Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.66 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 8/20 | 0.46 |
| ▸ | HTR1A | P08908 | 6/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3122433 | 0.84 | SLC6A4 (0.70) | DRD2SLC6A4CHRM4HTR1AADRA1D | |
| SCHEMBL6707211 | 0.79 | DRD2 (0.63) | DRD2SLC6A4HTR7HTR1AHTR2A | |
| SCHEMBL3380970 | 0.76 | SLC6A4 (0.71) | DRD2SLC6A4HTR7HTR2AADRA1D | |
| SCHEMBL3115404 | 0.76 | DRD2 (0.51) | DRD2SLC6A4HTR7 | |
| SCHEMBL6788939 | 0.76 | DRD2 (0.50) | DRD2SLC6A4HTR7ADRA1D | |
| SCHEMBL6968572 | 0.75 | DRD2 (0.66) | DRD2SLC6A4ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL11877059 | 0.75 | SLC6A4 (0.72) | DRD2SLC6A4CHRM4HTR1AHTR2A | |
| SCHEMBL6755250 | 0.75 | DRD2 (0.67) | DRD2SLC6A4CHRM4HTR1AHTR2A | |
| SCHEMBL7993011 | 0.73 | DRD2 (0.58) | DRD2SLC6A4CHRM4HTR1AHTR2A | |
| SCHEMBL3119619 | 0.73 | HTR1A (0.46) | DRD2SLC6A4HTR7HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | claimed |
| EP-1351936-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | claimed |
| WO-2002055496-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | claimed |
| US-9023656-B2 | Reactive mass labels | ELECTROPHORETICS LIMITED (GB) | 2015-05-05 | — | — | US | disclosed |
| EP-1907860-B1 | MASS LABELS | ELECTROPHORETICS LTD (GB) | 2010-11-17 | — | — | EP | disclosed |
| US-20100178710-A1 | Mass Labels | ELECTROPHORETICS LIMITED (GB) | 2010-07-15 | — | — | US | disclosed |
| EP-1907860-A2 | MASS LABELS | Electrophoretics Limited (GB) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007012849-A2 | MASS LABELS FOR BIOMOLECULES CONTAINING A 2,6-DIMETHYL-PIPERIDIN-l-YL METHYLENE OR A PYRIMIDIN-2-YL THIOMETHYLENE MASS MARKER MOIETY AND A SUCCINIMID-OXY-CARBONYL REACTIVE FUNCTIONAL GROUP | ELECTROPHORETICS LIMITED (GB) | 2007-02-01 | — | — | WO | disclosed |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| EP-1351936-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055496-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178710-A1 | Mass Labels | B2M, SRRM2, CCNB1 | DRD2 3923/4885SLC6A4 4579/4885CHRM4 524/4885 |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | LDLR, NR1H2, NCOR1 | DRD2 1008/4885SLC6A4 2034/4885CHRM4 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.